Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
Welf PragerDermatologikum Hamburg, Hamburg, GermanyObjectives: This review examines the pharmacologic and clinical characteristics of incobotulinumtoxinA (Xeomin®/Xeomeen®/Bocouture®/XEOMIN Cosmetic™; botulinum toxin type A [150 kDa]), which is free...
Guardado en:
Autor principal: | Prager W |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5880265a31234a43a39317edae50b97a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
por: Prager W, et al.
Publicado: (2013) -
“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
por: Mingqi Wang, et al.
Publicado: (2021) -
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park J, et al.
Publicado: (2011) -
NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines
por: North WG, et al.
Publicado: (2015) -
Management of antipsychotic treatment discontinuation and interruptions using model-based simulations
por: Samtani MN, et al.
Publicado: (2012)